Preventing viral relapse with prophylactic tenofovir in hepatitis B carriers receiving chemotherapy: a phase IV randomized study in Taiwan
ConclusionsThe 24-week preventative TDF has comparable efficacy to the 48-week treatment in virologic and clinical relapse. High baseline HBsAg or HBV DNA is associated with a higher risk of HBV relapse. These findings imply a 24-week duration of TDF treatment with a close monitor for patients with a high baseline viral load.Lay summaryHepatitis B virus infection is a prominent cause of liver cancer and chronic liver disease and affected millions of people worldwide. When HBV-infected people are exposed to immunosuppressive medication or chemotherapy for cancer, the chance of HBV reactivation rises considerably. This trial showed 24-week tenofovir disoproxil fumarate (TDF) may be sufficient for preventing HBV relapse in cancer patients receiving chemotherapy.Clinical Trial registration numberNCT02081469.
Source: Hepatology International - Category: Infectious Diseases Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Hepatitis | Hepatitis B | Infectious Diseases | Liver | Liver Disease | Phosphorus | Study | Taiwan Health | Urology & Nephrology | Viread | Virology | Vitamin D | Vitamins